Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

NIH reversed course on its policy barring scientists from attending scientific conferences and meetings without permission, ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Shares of Novavax Inc. NVAX rallied 7.92% to $5.86 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.06% to 16,724.46 ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the ...

Shares of Novavax Inc. NVAX tumbled 19.56% to $5.43 Thursday, on what proved to be an all-around dismal trading session for ...

April 10 (Reuters) - Vaccine maker Novavax's (NVAX.O), opens new tab shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised ...

Peer-reviewed journals rejected their followup study on the 2023-2024 formulation of mRNA vaccines against the JN.1 variant ...

In an emailed statement to The Fly, Novavax (NVAX) said, “As we have previously stated, we believe that our Biologics License Application for ...